BioNxt Solutions Inc. (CVE:BNXT) | WebDisclosure

Basculer en Français

9811	Companies
196812	Keywords
127831	Articles
104640	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

BRIEF

published on 10/02/2025 at 09:10, 4 months 3 days ago

BioNxt Advances Targeted Chemotherapy Drug Delivery Platform

Biopharmaceutical Drug Delivery Research Advancements BioNxt Solutions Targeted Chemotherapy
PRESS RELEASE

published on 10/02/2025 at 09:05, 4 months 3 days ago

BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform
BioNxt Solutions Inc. reports significant advancement in targeted chemotherapy delivery platform and upcoming definitive agreement. Proprietary technology aims at 10-fold increase in therapeutic effect while safeguarding healthy cells

BioNxt Solutions Inc. Oncology Treatments Chemotherapy Delivery Platform Targeted Drug Delivery System Therapeutic Effect
BRIEF

published on 09/29/2025 at 09:10, 4 months 6 days ago

BioNxt fait progresser le développement d'un médicament sublingual à base de cladribine pour le traitement de la sclérose en plaques

Sclérose En Plaques Cladribine Développement De Médicaments Biodisponibilité Sublingual
BRIEF

published on 09/29/2025 at 09:10, 4 months 6 days ago

BioNxt Advances Cladribine Sublingual Drug Development for Multiple Sclerosis

Drug Development Multiple Sclerosis Cladribine Bioavailability Sublingual
PRESS RELEASE

published on 09/29/2025 at 09:05, 4 months 6 days ago

BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization
BioNxt Solutions provides update on Cladribine sublingual thin-film drug reformulation program, targeting treatment of multiple sclerosis with improved bioavailability and patient adherence

Multiple Sclerosis Cladribine Neurological Disorders BioNxt Solutions Drug Delivery Technologies
BRIEF

published on 09/20/2025 at 03:50, 4 months 15 days ago

BioNxt Solutions lève des actions pour régler sa dette

Actions Ordinaires Règlement De La Dette Solutions BioNxt Valeurs Mobilières Canadiennes Accord De Dette
BRIEF

published on 09/20/2025 at 03:50, 4 months 15 days ago

BioNxt Solutions Completes Shares for Debt Settlement

Common Shares Debt Settlement Debt Agreement Canadian Securities BioNxt Solutions
PRESS RELEASE

published on 09/20/2025 at 03:45, 4 months 15 days ago

BioNxt Solutions Announces Closing of Shares for Debt Settlement
BioNxt Solutions Inc. announces successful debt settlement with creditor, issuing common shares and making cash payment. Company focuses on bioscience innovation and drug delivery technologies

Common Shares Debt Settlement BioNxt Solutions Inc. Drug Delivery Technologies Bioscience Innovation
BRIEF

published on 09/20/2025 at 01:35, 4 months 15 days ago

BioNxt Solutions Inc. fait appel à des conseillers en marchés financiers et à des professionnels des relations avec les investisseurs.

Relations Avec Les Investisseurs Marchés Des Capitaux Options Sur Actions Solutions BioNxt Terry Lynch
BRIEF

published on 09/20/2025 at 01:35, 4 months 15 days ago

BioNxt Solutions Inc. Engages Capital Markets Advisor and Investor Relations Professionals

Stock Options Investor Relations Capital Markets BioNxt Solutions Terry Lynch

Accesswire

Published on 02/05/2026 at 15:10, 18 minutes ago

Electric Metals (USA) Limited Announces Change of Auditor
Published on 02/05/2026 at 14:50, 38 minutes ago

High Tide Resources Announces Non-Brokered Private Placements
Published on 02/05/2026 at 14:30, 58 minutes ago

Electrovaya Announces Date for Q1-2026 Financial Results & Conference Call
Published on 02/05/2026 at 14:30, 58 minutes ago

Innodata to Report Fourth Quarter and Fiscal Year 2025 Results
Published on 02/05/2026 at 14:00, 1 hour 28 minutes ago

Organto Foods Inc. Expects Strong 2026 Growth Driven by Retail Wins and Expanded Supply Partnerships

View all ACCESSWIRE

EQS Group

Published on 02/05/2026 at 15:15, 13 minutes ago

FIS SUCCESSFULLY COMPLETES €770 MILLION BOND ISSUANCE
Published on 02/05/2026 at 15:13, 15 minutes ago

Form 8.3 - The Vanguard Group, Inc.: JTC plc
Published on 02/05/2026 at 15:12, 15 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Glencore plc
Published on 02/05/2026 at 15:12, 16 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 02/05/2026 at 15:11, 17 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Beazley plc

Les Echos

Published on 02/05/2026 at 11:30, 3 hours 58 minutes ago

Déclaration nombre d'actions et droits de vote - 05.02.2026
Published on 02/05/2026 at 11:30, 3 hours 58 minutes ago

Disclosure of shares outstanding and voting rights - 05.02.2026
Published on 02/04/2026 at 18:04, 21 hours 24 minutes ago

Capital et droits de vote au 31 janvier 2026
Published on 02/04/2026 at 18:04, 21 hours 24 minutes ago

Total number of voting rights and shares making up the share capital at January 31, 2026
Published on 02/04/2026 at 17:45, 21 hours 43 minutes ago

Information concerning the total number of voting rights and shares 2026 01 31

View all LES ECHOS COMFI WIRE